Oral treprostinil is a prostacyclin analogue approved to treat pulmonary arterial hypertension (PAH). A study analysing the practical management of oral treprostinil in patients with pulmonary arterial hypertension has been published on “Respiratory Medicine” Volume 231, 107734, September 2024. The article is based on results of the ADAPT and EXPEDITE trials and expert consensus.
The multicenter, prospective, real-world, observational ADAPT Registry study followed adult patients with pulmonary arterial hypertension for up to 78 weeks after initiating oral treprostinil. The EXPEDITE clinical trial prospectively evaluated the effectiveness of a short course of IV/SC induction therapy on the tolerability and time to effective dosing with oral treprostini.l
The article is open access and available at this link
Respiratory Medicine, Volume 231, 107734, September 2024 Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus, Jacqueline Brewer, Melisa Wilson, James C. Coons, Ann Schmit, Mary E. Whittenhall, Amy Kimber, Meredith Broderick, Dasom Lee, Natalie Patzlaff, Chad Miller, Ali Ataya, Valerie LaRoy, Christopher S. King, Ashwin K. Ravichandran, John F. Kingrey, Sandeep Sahay. Open Access Published:July 08, 2024 DOI:https://doi.org/10.1016/j.rmed.2024.107734